Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: A randomized controlled trial

Addiction

Volumn 106, Issue 7, 2011, Pages 1309-1318

  Everly, Jeffrey J ^b   Defulio, Anthony ^a   Koffarnus, Mikhail N ^a   Leoutsakos, Jeannie Marie S ^a   Donlin, Wendy D ^c   Aklin, Will M ^d   Umbricht, Annie ^a   Fingerhood, Michael ^a   Bigelow, George E ^a   Silverman, Kenneth ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Pittsburgh   (United States)

^c UNIVERSITY OF NORTH CAROLINA WILMINGTON   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Contingency management; Depot naltrexone; Drug addiction; Employment; Employment based reinforcement; Heroin; Naltrexone; Reinforcement; Substance abuse; Unemployment

Indexed keywords

COCAINE; DOPAMINE UPTAKE INHIBITOR; NALTREXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; EMPLOYMENT; FEMALE; HUMAN; MALE; MIDDLE AGED; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; SALARY AND FRINGE BENEFIT; STATISTICS; SUBCUTANEOUS DRUG ADMINISTRATION; URINE;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; COCAINE; DELAYED-ACTION PREPARATIONS; DOPAMINE UPTAKE INHIBITORS; EMPLOYMENT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); REINFORCEMENT (PSYCHOLOGY); SALARIES AND FRINGE BENEFITS; YOUNG ADULT;

EID: 79958005224     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03400.x     Document Type: Article

References (38)

1. McLellan A. T., Lewis D. C., O'Brien C. P., Kleber H. D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284: 1689-95.
2. Hser Y. I., Hoffman V., Grella C. E., Anglin M. D. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001; 58: 503-8.
3. Vaillant G. E. A 20-year follow-up of New York narcotic addicts. Arch Gen Psychiatry 1973; 29: 237-41.
4. Galai N., Safaeian M., Vlahov D., Bolotin A., Celentano D. D., for the ALIVE Study. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort, 1988-2000: description and determinants. Am J Epidemiol 2003; 158: 695-704.
5. Brewer D. D., Catalano R. F., Haggerty K., Gainey R. R., Fleming C. B. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 1998; 93: 73-92.
6. Magura S., Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001; 68: 62-74.
7. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. National consensus development panel on effective medical treatment of opiate addiction. JAMA 1998; 280: 1936-43.
8. Sees K. L., Delucchi K. L., Masson C., Rosen A., Clark H. W., Robillard H. etal. Methadone maintenance versus 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000; 283: 1303-10.
9. Martin W. R., Jasinski D. R., Mansky P. A. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry 1973; 28: 784-91.
10. Mello N. K., Mendelson J. H., Kuehnle J. C., Sellers M. S. Operant analysis of human heroin self-administration and the effects of naltrexone. J Pharmacol Exp Ther 1981; 216: 45-54.
11. Schuh K. J., Walsh S. L., Stitzer M. L. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl) 1999; 145: 162-74.
12. Walsh S. L., Sullivan J. T., Preston K. L., Garner J. E., Bigelow G. E. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther 1996; 279: 524-38.
13. Sullivan M. A., Garawi F., Bisaga A., Comer S. D., Carpenter K., Raby W. N. etal. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007; 91: 289-92.
14. Comer S. D., Sullivan M. A., Hulse G. K. Sustained-release naltrexone: novel treatment for opioid dependence. Exp Opin Invest Drugs 2007; 16: 1285-94.
15. Adi Y., Juarez-Garcia A., Wang D., Jowett S., Frew E., Day E. etal. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess 2007; 11: iii, iv, 1-85.
16. Modesto-Lowe V., Van Kirk J. Clinical uses of naltrexone: a review of the evidence. Exp Clin Psychopharmacol 2002; 10: 213-27.
17. Comer S. D., Collins E. D., Kleber H. D., Nuwayser E. S., Kerrigan J. H., Fischman M. W. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) 2002; 159: 351-60.
18. Comer S. D., Sullivan M. A., Yu E., Rothenberg J. L., Kleber H. D., Kampman K. etal. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 210-8.
19. Rounsaville B. J. Can psychotherapy rescue naltrexone treatment of opioid addiction? NIDA Res Monogr 1995; 150: 37-52.
20. Grabowski J., O'Brien C. P., Greenstein R., Ternes J., Long M., Steinberg-Donato S. Effects of contingent payment on compliance with a naltrexone regimen. Am J Drug Alcohol Abuse 1979; 6: 355-65.
21. Preston K. L., Silverman K., Umbricht A., DeJesus A., Montoya I. D., Schuster C. R. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 1999; 54: 127-35.
22. Carroll K. M., Sinha R., Nich C., Babuscio T., Rounsaville B. J. Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude. Exp Clin Psychopharmacol 2002; 10: 54-63.
23. Carroll K. M., Ball S. A., Nich C., O'Connor P. G., Eagan D. A., Frankforter T. L. etal. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 2001; 58: 755-61.
24. Silverman K. Exploring the limits and utility of operant conditioning in the treatment of drug addiction. Behav Anal 2004; 27: 209-30.
25. Silverman K., Svikis D., Robles E., Stitzer M. L., Bigelow G. E. A reinforcement-based therapeutic workplace for the treatment of drug abuse: six-month abstinence outcomes. Exp Clin Psychopharmacol 2001; 9: 14-23.
26. Silverman K., Svikis D., Wong C. J., Hampton J., Stitzer M. L., Bigelow G. E. A reinforcement-based therapeutic workplace for the treatment of drug abuse: three-year abstinence outcomes. Exp Clin Psychopharmacol 2002; 10: 228-40.
27. Silverman K., Wong C. J., Needham M., Diemer K. N., Knealing T., Crone-Todd D. etal. A randomized trial of employment-based reinforcement of cocaine abstinence in injection drug users. J Appl Behav Anal 2007; 40: 387-410.
28. Donlin W. D., Knealing T. W., Needham M., Wong C. J., Silverman K. Attendance rates in a workplace predict subsequent outcome of employment-based reinforcement of cocaine abstinence in methadone patients. J Appl Behav Anal 2008; 41: 499-516.
29. DeFulio A., Donlin W. D., Wong C. J., Silverman K. Employment-based abstinence reinforcement as a maintenance intervention for the treatment of cocaine dependence: a randomized controlled trial. Addiction 2009; 104: 1530-8.
30. American Psychiatric Association, Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
31. Knealing T. W., Roebuck M. C., Wong C. J., Silverman K. Economic cost of the therapeutic workplace intervention added to methadone maintenance. J Subst Abuse Treat 2008; 34: 326-32.
32. McLellan A. T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H. L. etal. New data from the addiction severity index. Reliability and validity in three centers. J Nerv Ment Dis 1985; 173: 412-23.
33. Navaline H. A., Snider E. C., Petro C. J., Tobin D., Metzger D., Alterman A. I. etal. Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors. AIDS Res Hum Retroviruses 1994; 10: S281-3.
34. Compton W. M., Cottler L. B., Dorsey K. B., Spitznagel E. L., Mager D. E. Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN. Drug Alcohol Depend 1996; 41: 179-87.
35. Wilkinson G. S. WRAT-3: Wide Range Achievement Test Administration Manual. Wilmington, DE: Wide Range, Inc.; 1993.
36. Silverman K., Robles E., Mudric T., Bigelow G. E., Stitzer M. L. A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugs. J Consult Clin Psychol 2004; 72: 839-54.
37. Zeger S. L., Liang K. Y., Albert P. S. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44: 1049-60.
38. Singer J. D. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat 1998; 24: 323-55.